RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Some drugs can activate AMPK, most prominently metformin, which is approved for diabetes and being trialed in dementia. Less well-known is aldometanib, developed by Lin’s team, which blocks aldolase, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.

Figure 1. Chronological order of discovery of antimicrobial peptides ... These peptides mainly act as ligands binding to Toll-like receptors transmitting signals via MAPK or TLR1/2 pathways enhancing ...

This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. As an approach to optimize efficacy and minimize side effects, co-agonists ...

Some preclinical studies and human case reports have found glucagon-like peptide-1 receptor (GLP-1) agonists reduced alcohol consumption, though they are only approved for diabetes and obesity ...

Study: Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective. Image Credit: crystal light / Shutterstock ...

GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists Between 25% and 75% of all cases of hypertension are attributable to obesity. GLP-1 ...